dimirel glimepiride 4mg tablet blister pack
sanofi-aventis australia pty ltd - glimepiride, quantity: 4 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; sodium starch glycollate; povidone; microcrystalline cellulose; indigo carmine - dimirel is indicated as an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with non-insulin-dependent (type 2) diabetes mellitus.
dimirel glimepiride 3mg tablet blister pack
sanofi-aventis australia pty ltd - glimepiride, quantity: 3 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; iron oxide yellow; sodium starch glycollate; povidone; lactose monohydrate; magnesium stearate - dimirel is indicated as an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with non-insulin-dependent (type 2) diabetes mellitus.
dimirel glimepiride 2mg tablet blister pack
sanofi-aventis australia pty ltd - glimepiride, quantity: 2 mg - tablet, uncoated - excipient ingredients: iron oxide yellow; magnesium stearate; microcrystalline cellulose; povidone; lactose monohydrate; indigo carmine; sodium starch glycollate - dimirel is indicated as an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with non-insulin-dependent (type 2) diabetes mellitus.
dimirel glimepiride 1mg tablet blister pack
sanofi-aventis australia pty ltd - glimepiride, quantity: 1 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; lactose monohydrate; iron oxide red; magnesium stearate; povidone; microcrystalline cellulose - dimirel is indicated as an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with non-insulin-dependent (type 2) diabetes mellitus.
mirena- levonorgestrel intrauterine device
bayer healthcare pharmaceuticals inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw) - levonorgestrel 52 mg - mirena is indicated for prevention of pregnancy for up to 8 years; replace after the end of the eighth year. mirena is indicated for the treatment of heavy menstrual bleeding for up to 5 years in women who choose to use intrauterine contraception as their method of contraception; replace after the end of the fifth year if continued treatment of heavy menstrual bleeding is needed. the use of mirena is contraindicated when one or more of the following conditions exist: the use of mirena is contraindicated in pregnancy or with a suspected pregnancy and mirena may cause adverse pregnancy outcomes [see contraindications (4 ), warnings and precautions (5.1 , 5.2 )]. if a woman becomes pregnant with mirena in place, the likelihood of ectopic pregnancy is increased and there is an increased risk of miscarriage, sepsis, premature labor, and premature delivery. remove mirena, if possible, if pregnancy occurs in a woman using mirena. if mirena cannot be removed, follow the pregnancy closely [see warnings and precautio
mirena levonorgestrel 52mg intrauterine drug delivery system sachet
bayer australia ltd - levonorgestrel, quantity: 52 mg - drug delivery system, intrauterine - excipient ingredients: dimethylsiloxane/methylvinylsiloxane cross linked elastomer - contraception. treatment of idiopathic menorrhagia. prevention of endometrial hyperplasia during oestrogen replacement therapy.
mirex termite bait
agriculture protection board of western australia - mirex - insecticide - tree - see label for variety - giant termite | giant northern termite
mirena
bayer new zealand limited - levonorgestrel 52mg - intrauterine contraceptive device - 52 mg - active: levonorgestrel 52mg - contraception
mirena
bayer israel ltd - levonorgestrel - intrauterine device - levonorgestrel 52 mg - levonorgestrel and estrogen - levonorgestrel and estrogen - contraception and idiopathic menorrhagia. protection from endometrial hyperplasia during estrogen replacement therapy.
mirena
bayer israel ltd - levonorgestrel - intrauterine device - levonorgestrel 52 mg - levonorgestrel and estrogen - contraception and idiopathic menorrhagia. protection from endometrial hyperplasia during estrogen replacement therapy.